Literature DB >> 21731027

The IL-28B genotype predicts which slow-responding hepatitis C-infected patients will benefit from treatment extension.

Brian L Pearlman, Carole Ehleben.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21731027     DOI： 10.1038/ajg.2011.149

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  4 in total

Review 1.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 2.  IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.

Authors:  Christoph T Berger; Arthur Y Kim
Journal:  Infect Dis Clin North Am       Date:  2012-12       Impact factor: 5.982

3.  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Authors:  María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino
Journal:  BMC Med       Date:  2013-01-08       Impact factor: 8.775

Review 4.  Host genetic variants in the pathogenesis of hepatitis C.

Authors:  Monika Rau; Katharina Baur; Andreas Geier
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.